graph Evidence gap map comparisons
atezolizumab based treatmentdurvalumab based treatmentpembrolizumab based treatment
atezolizumab plus carboplatin plus nab-paclitaxel atezolizumab plus nab-paclitaxel atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide atezolizumab plus paclitaxel durvalumab alone pembrolizumab alone pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide pembrolizumab plus SoC
Comparator:  vs placebo;   vs paclitaxel followed by doxorubicin plus cyclophosphamide;   vs carboplatin plus nab-paclitaxel;   vs placebo plus SoC;   vs Standard of Care (SoC); 
Risk of bias:  low;   some concerns;   high;  NA;